Indegene Ltd
Incorporated in 1998, Indegene Ltd provides
solutions consisting of analytics, technology
and commercial, medical, regulatory and
safety services to life science and health
care organizations[1]
- Market Cap ₹ 14,005 Cr.
- Current Price ₹ 581
- High / Low ₹ 627 / 414
- Stock P/E 33.6
- Book Value ₹ 130
- Dividend Yield 0.39 %
- ROCE 18.8 %
- ROE 14.4 %
- Face Value ₹ 2.00
Pros
- Company is almost debt free.
- Company is expected to give good quarter
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|
| 553 | 643 | 966 | 1,665 | 2,306 | 2,590 | 2,839 | 3,510 | 3,813 | |
| 511 | 499 | 736 | 1,378 | 1,910 | 2,084 | 2,292 | 2,892 | 3,175 | |
| Operating Profit | 42 | 144 | 230 | 287 | 396 | 505 | 548 | 619 | 638 |
| OPM % | 8% | 22% | 24% | 17% | 17% | 20% | 19% | 18% | 17% |
| 7 | -102 | -3 | -21 | 58 | 79 | 94 | 52 | 59 | |
| Interest | 6 | 9 | 7 | 6 | 31 | 49 | 22 | 19 | 22 |
| Depreciation | 17 | 19 | 26 | 33 | 60 | 76 | 80 | 126 | 149 |
| Profit before tax | 26 | 14 | 195 | 226 | 363 | 459 | 539 | 525 | 526 |
| Tax % | 45% | 191% | 23% | 28% | 27% | 27% | 25% | 24% | |
| 14 | -12 | 149 | 163 | 266 | 337 | 407 | 401 | 401 | |
| EPS in Rs | 89.98 | -40.20 | 951.96 | 937.73 | 11.99 | 15.14 | 16.95 | 16.65 | 16.66 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 12% | 13% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 29% |
| 3 Years: | 15% |
| TTM: | 30% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 23% |
| 3 Years: | 16% |
| TTM: | -4% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | 6% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 21% |
| 3 Years: | 19% |
| Last Year: | 14% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.31 | 0.31 | 0.31 | 0.35 | 44 | 44 | 48 | 48 |
| Reserves | 73 | -105 | 324 | 764 | 1,020 | 1,385 | 2,568 | 3,091 |
| 147 | 483 | 51 | 66 | 502 | 490 | 102 | 144 | |
| 108 | 222 | 220 | 524 | 638 | 627 | 609 | 1,337 | |
| Total Liabilities | 329 | 600 | 596 | 1,353 | 2,204 | 2,546 | 3,326 | 4,620 |
| 104 | 119 | 86 | 138 | 664 | 646 | 678 | 1,812 | |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 12 |
| Investments | 0 | 13 | 0 | 120 | 614 | 796 | 1,290 | 1,100 |
| 225 | 468 | 510 | 1,096 | 926 | 1,103 | 1,355 | 1,697 | |
| Total Assets | 329 | 600 | 596 | 1,353 | 2,204 | 2,546 | 3,326 | 4,620 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| 65 | 22 | 172 | 297 | 130 | 508 | 442 | 651 | |
| -18 | -16 | -81 | -158 | -896 | -326 | -677 | -508 | |
| -21 | 136 | -132 | 233 | 333 | -66 | 288 | -83 | |
| Net Cash Flow | 25 | 143 | -40 | 373 | -433 | 115 | 52 | 60 |
| Free Cash Flow | 48 | 16 | 151 | 272 | 111 | 497 | 412 | 606 |
| CFO/OP | 196% | 34% | 96% | 128% | 60% | 125% | 110% | 129% |
Ratios
Consolidated / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 60 | 127 | 108 | 97 | 102 | 91 | 97 | 102 |
| Inventory Days | ||||||||
| Days Payable | ||||||||
| Cash Conversion Cycle | 60 | 127 | 108 | 97 | 102 | 91 | 97 | 102 |
| Working Capital Days | -7 | -5 | 45 | 11 | 41 | 27 | 39 | 5 |
| ROCE % | 37% | 55% | 46% | 33% | 29% | 25% | 19% |
Insights
In beta| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Active Client Relationships Count |
|
||||||
| Total Employees Count |
|||||||
| $1M+ Clients Count |
|||||||
| $25M+ Strategic Clients Count |
|||||||
| Net Revenue Retention % |
|||||||
| Top 20 Customer Revenue INR Mn |
|||||||
| Revenue per Employee USD |
|||||||
Extracted by Screener AI
Documents
Announcements
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
- Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
- Indegene issued a press release on its Digital Summit 2026 in Philadelphia, highlighting AI and client engagement themes.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
- Indegene Q2 FY27 earnings call scheduled for 30 October 2026 at 8:00 AM IST.
-
Board Meeting Intimation for Consideration Of The Unaudited Standalone And Consolidated Financial Results For The Quarter And Half Year Ended September 30, 2026 Along With The Limited Review Report Of The Auditors Thereon.
- Board meets 29 Oct 2026 to approve Q2/H1 FY27 results and RSU/ESOP allotment.
Annual reports
-
Annual Report 2026
from bse
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
Concalls
-
Aug 2026Transcript PPT REC
-
May 2026PPT
-
May 2026Transcript PPT REC
-
Apr 2026PPT
-
Feb 2026Transcript PPT REC
-
Nov 2025Transcript PPT
-
Oct 2025Transcript PPT REC
-
Aug 2025Transcript PPT
-
May 2025Transcript PPT REC
-
Mar 2025PPT
-
Feb 2025Transcript PPT
-
Nov 2024Transcript PPT
-
Aug 2024Transcript PPT
-
Aug 2024PPT
-
Jun 2024Transcript REC
Business Overview [1]
The company is a strategic operating partner to the global life sciences industry, supporting commercial, medical, R&D, and safety operations across the product lifecycle. It combines deep life sciences expertise with AI-enabled platforms, data analytics, and governed operating models, servicing the world’s top 20 biopharma companies. Its capabilities span five key areas: Discovery & Evidence, Regulatory & Compliance, Commercial Launch, Content & Engagement, and Patient & Outcomes.